SEC Form 4 · accession 0001445064-16-000239
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael-Bryant Hicks
Officer — Sr. VP & General Counsel
Period of report
Apr 1, 2016
Accepted (ET)
Apr 5, 2016 · 8:35 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Apr 1, 2016 | A | 3,110 | $0.00 | A | 3,110 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Share Options (Right to Buy)F2 | $64.31 | Apr 1, 2016 | A | 19,377 | A | Apr 1, 2017 | Apr 1, 2026 | Ordinary Shares | 19,377 | 19,377 | D |
Explanation of responses
- F1Represents restricted stock units that vest in four equal annual installments beginning April 1, 2017.
- F2The options vest in four equal annual installments beginning April 1, 2017.